Dr. Lal Path Labs Ltd. has informed the Exchange about re-appointment of Auditor(s):1. M/s Ernst & Young LLP (EY) as the Internal Auditors of the Company for the Financial Year 2026-27.2. M/s A.G. Agarwal & Associates as the Cost Auditors of the Company for the Financial Year 2026-27.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Lal Path Labs reported strong FY26 results with total income of INR 28,642 million (up 12% YoY) and profit of INR 5,098 million (up 4% YoY). The Board recommended a final dividend of INR 4 per share, bringing total dividend for FY26 to INR 20.5 per share. Key strategic moves include acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited and incorporation of a new wholly-owned subsidiary in Dubai. The company also re-appointed Dr. Arvind Lal as Executive Chairman for 5 years and Mr. Rajit Mehta as Independent Director for 5 years. Ernst & Young LLP was re-appointed as Internal Auditors and A.G. Agarwal & Associates as Cost Auditors for FY26-27. The 32nd AGM is scheduled for July 25, 2026.
The filing shows healthy operational performance with revenue growth and consistent dividend payouts. The acquisition and international expansion signal growth focus. Continuity in leadership and auditor appointments suggests stable governance, which should be positive for investor confidence.